* Viking Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on October 23 for the period ending January 1 0001
*
* LSEG's mean analyst estimate for Viking Therapeutics Inc is for a loss of 25 cents per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Viking Therapeutics Inc is $118.00, above its last closing price of $65.80.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.28 -0.27 -0.20 Beat 25.9
Mar. 31 2024 -0.28 -0.28 -0.26 Beat 6.5
Jan. 1 0001 -0.26 -0.25 -0.25 Met 1.3
Sep. 30 2023 -0.22 -0.22 -0.23 Missed -5
Jun. -0.19 -0.19 -0.19 Met 1.2
30 2023
Mar. 31 2023 -0.24 -0.24 -0.25 Missed -4.2
Dec. 31 2022 -0.24 -0.23 -0.26 Missed -12.2
Jan. 1 0001 -0.23 -0.23 -0.21 Beat 9.1
This summary was machine generated October 21 at 21:40 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
